What does Statinagi 20 do?

This is an automatically translated article.

Statinagi 20 is a product with the active ingredient Atorvastatin, which is indicated in the treatment of hypercholesterolemia and prevention of cardiovascular disease. To ensure the effectiveness of treatment as well as avoid side effects, patients need to take medicine according to prescription or consult a doctor or pharmacist for advice.

1. What are the effects of Statinagi 20mg?

Statinagi 20 is indicated for the treatment of the following diseases:
1.1. Hypercholesterolemia Atorvastatin is indicated in the treatment of cases of hypercholesterolemia to help reduce total cholesterol (total C), apolipoprotein B, low-density lipoprotein cholesterol (LDL-C) and triglycerides. The age of use is often diverse, including adults, adolescents and children 10 years of age and older with primary hypercholesterolemia and including heterozygous familial hypercholesterolemia, The patient did not respond to diet and other non-pharmacological treatments. In addition, Atorvastatin is indicated for the reduction of total C and LDL-C in adults with homozygous familial hypercholesterolemia as an adjunct to other treatments. other lipid-lowering.
1.2. Help prevent cardiovascular diseases Adult patients can use the drug to prevent cardiovascular complications in the early stages and help regulate other risk factors.

2. Pharmacodynamics of Statinagi 20

Atorvastatin acts as a selective inhibitor and acts on inhibition of HMG-CoA reductase metabolism. This enzyme has the decisive ability to inhibit the metabolism to form precursors of steroids and cholesterol.

3. Pharmacokinetics of Statinagi 20

Atorvastatin is rapidly absorbed into the body and reaches peak plasma concentrations after 1 to 2 hours. Plasma concentrations and absorption of atorvastatin are proportional to the dose of atorvastatin. The bioavailability of film-coated tablets is approximately 95% to 99% of that of the solution.
Atorvastatin and its metabolites are metabolized in the liver or outside the liver, and then eliminated mainly in the bile. The mean plasma half-life of the drug is approximately 14 hours, whereas the half-life of inhibitory activity for HMG-CoA reductase is 20-30 hours due to the contribution of metabolites. active.

4. How to use Statinagi 20

The drug is used in oral form and takes a single dose at any time of the day, can be taken before or after meals. During treatment, patients should follow a standard cholesterol-lowering diet throughout treatment. Dosage varies from patient to patient depending on baseline LDL-C levels, treatment goals, and patient response status. The starting dose is usually 10mg daily and maintained for about 4 weeks or more. The maximum dose is 80mg per day. Depending on the disease, the dosage can be maintained and adjusted as follows:
Combination of hyperlipidemia and primary hypercholesterolemia can be controlled with 10 mg of atorvastatin once daily. The disease will have a good improvement within the first 2 weeks and a maximum response in 4 weeks and can be maintained for a long time. Patients with heterozygous hereditary hypercholesterolemia may be started with 10 mg daily. It is then titrated 4 weeks up to 40 mg/day and may be increased to a maximum of 80 mg/day. Alternatively, some people may be prescribed a combination of a bile acid sequestrant with atorvastatin 40 mg once daily. Homozygous Familial Hypercholesterolemia: Studies in this group of patients are still very limited, so their dose of atorvastatin remains 10 mg to 80 mg/day. May be combined with other lipid-lowering methods. Supportive treatment for cardiovascular disease prevention: Start at 10 mg/day and may titrate higher to achieve LDL-C levels according to current guidelines. Renal impairment: No dose adjustment is required in this patient. Hepatic impairment: Atorvastatin is contraindicated in patients with advanced liver disease. In addition, caution should be exercised in the use of this drug in patients with hepatic impairment. It should be noted that the above dosage is for reference only. For each individual patient will be considered to adjust the dose depending on the condition and the disease progression. Therefore, you need to consult and discuss with a medical professional to get the right dose.
Statinagi 20 has some contraindications as follows:
Hypersensitivity to atorvastatin or to any ingredient in the drug. Patients with advanced liver disease or unexplained persistent elevations in serum transaminase levels 3 times the upper limit of normal. Women who are pregnant or breastfeeding. There is no specific treatment when using Statinagi 20 overdose. Therefore, when a patient accidentally overdoses, it is possible to treat symptoms with supportive measures when necessary. At the same time, liver function should be checked and plasma concentrations monitored.
Because of its strong plasma protein binding, hemodialysis is difficult and can significantly increase clearance of atorvastatin.

5. Some notes when using Statinagi 20

At the start of treatment, patients should have liver function tests to detect any signs or symptoms of liver damage. If transaminase levels are elevated, they should be monitored until they return to normal. In cases where this index increases to 3 times the upper limit of normal, the dose should be reduced or the drug discontinued.
Caution should be exercised in patients with a history of liver disease, heavy drinkers should be monitored until abnormalities resolve. If transaminase elevation exceeds 3 times the upper limit of normal (ULN), reduce dose or discontinue atorvastatin.
Atorvastatin should be used with caution in patients who consume a lot of alcohol and/or have a history of liver disease.
Atorvastatin has the potential to interact with the following drugs:
Inhibitors of CYP3A4 when co-administered with Atorvastatin may increase plasma concentrations of atorvastatin and may cause myopathy. Therefore, concomitant use of strong CYP3A4 inhibitors eg: ciclosporin, delavirdin, telithromycin, stiripentol, posaconazole, ketoconazole, voriconazole, clarithromycin, itraconazole and HIV protease inhibitors such as ritonavir, atazanavir, darunavir, is not recommended. lopinavir, indinavir, ... Inducers of CYP3A4 when co-administered with atorvastatin may result in decreased plasma concentrations of atorvastatin. Concomitant use of transporter protein inhibitors may unduly increase the bioavailability of atorvastatin. Statinagi 20 is a product with the active ingredient Atorvastatin indicated in the treatment of hypercholesterolemia and prevention of cardiovascular disease. To ensure effective treatment as well as avoid side effects, users need to carefully read the instructions for use or consult a doctor or pharmacist for advice.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.